A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

NCT05681728 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences